<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital heart disease: Prenatal screening, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital heart disease: Prenatal screening, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital heart disease: Prenatal screening, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua Copel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prenatal identification and management of fetal cardiac abnormalities are important because congenital anomalies are a leading cause of infant death, and congenital heart disease (CHD) is the leading cause of death among infants with congenital anomalies. In the United States, CHD is diagnosed in approximately 1 percent of births, accounts for 4 percent of neonatal deaths, and accounts for 30 to 50 percent of deaths related to congenital anomalies [<a href="#rid1">1,2</a>]. In addition to cardiac morbidity and mortality, CHD is also associated with an increased risk for adverse neurodevelopmental outcome, which has been attributed to factors such as associated chromosomal abnormalities, other genetic abnormalities, syndromes, postnatal cardiac dysfunction, perioperative factors in infants who require surgical treatment, and possibly in utero hemodynamic abnormalities. In children with an isolated cardiac abnormality, the frequency of neurodevelopment abnormality also depends on the specific abnormality. </p><p>The full spectrum of cardiac abnormalities diagnosed in a postnatal population generally can be detected in the fetus, except for some minor lesions, such as secundum atrial septal defects, which are less likely to be diagnosed in the prenatal period, and patent ductus arteriosus, which is a normal fetal shunt.</p><p>This topic will present an overview of prenatal screening and diagnosis of CHD and management of affected pregnancies. Newborn screening and evaluation are reviewed separately. (See  <a class="medical medical_review" href="/d/html/101291.html" rel="external">"Newborn screening for critical congenital heart disease using pulse oximetry"</a> and  <a class="medical medical_review" href="/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a>.)</p><p class="headingAnchor" id="H184758498"><span class="h1">BENEFITS AND RISKS OF PRENATAL SCREENING AND DIAGNOSIS OF CHD</span></p><p class="headingAnchor" id="H376819738"><span class="h2">Benefits</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parental counseling and preparation</strong> – Prenatal diagnosis of CHD provides parents an opportunity to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain prognostic information prior to birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Learn about treatment options for their child before and after birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Make decisions concerning the management approach that is best for their family (eg, whether to terminate pregnancy or undergo in utero intervention, if available; nonintervention).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plan for specific needs at birth (eg, place, timing, and route of delivery; pediatric and obstetric providers; palliative care).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement in neonatal survival</strong> – Prenatal diagnosis of CHD may improve newborn survival and other outcomes [<a href="#rid3">3-6</a>], but data are limited despite substantial experience in the identification of fetal cardiac anomalies. </p><p></p><p class="bulletIndent1">In a meta-analysis of eight observational studies, prenatal diagnosis critical CHD reduced mortality prior to planned cardiac surgery compared with postnatal diagnosis (pooled odds ratio 0.26, 95% CI 0.08-0.84, 1 death/207 prenatal diagnoses versus 31 deaths/821 postnatal diagnoses) [<a href="#rid3">3</a>]. The analysis was limited to patients with comparable anatomy, standard risk, a parental desire to treat, and optimal care. The small number of deaths precludes a clear conclusion about the benefit of prenatal diagnosis, and the observed survival benefit may not apply to newborns who have a prenatal diagnosis of noncritical congenital heart abnormalities or who receive nonoptimal care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement in neonatal morbidity</strong> – Prenatal diagnosis of CHD has also been associated with a reduction in neonatal morbidity, including severe acidosis [<a href="#rid7">7</a>]. Neonates with congenital heart abnormalities that require patency of the ductus arteriosus for systemic or pulmonary blood flow can benefit from early postnatal intervention (prostaglandin E1) to prevent closure of the ductus [<a href="#rid8">8,9</a>]. Similarly, readiness to perform transcatheter intervention (eg, balloon atrial septostomy for neonates with d-transposition of the great arteries [TGA] or hypoplastic left heart syndrome [HLHS], balloon valvuloplasty for patients with critical pulmonic or aortic stenosis) or pacing of complete heart block soon after birth enables rapid stabilization of the postnatal circulation and thus may improve outcome [<a href="#rid2">2,8,10-13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible opportunity for fetal treatment</strong> – In some cases, prenatal diagnosis also provides an opportunity for in utero interventions. Transplacental medical therapy improves the prognosis of some fetal arrhythmias, particularly tachycardias (see  <a class="medical medical_review" href="/d/html/6765.html" rel="external">"Fetal arrhythmias"</a>). Invasive in utero cardiac intervention (eg, aortic or pulmonary balloon valvuloplasty [<a href="#rid14">14</a>], atrial needle septoplasty [<a href="#rid15">15</a>]) may improve the prognosis of some lesions, such as HLHS or severe valvular abnormalities (eg, severe aortic stenosis, pulmonary atresia); however, these interventions are performed at only a few fetal surgery centers and are considered investigational [<a href="#rid16">16,17</a>].</p><p></p><p class="headingAnchor" id="H3007226603"><span class="h2">Harms</span><span class="headingEndMark"> — </span>The main potential harm of screening for CHD prenatally is parental anxiety. A false-negative screen of a newborn with critical cardiac disease can result in birth at a facility unprepared to provide appropriate intervention or postnatal instability that is not appropriately treated because the cardiac cause has not been identified. Less commonly, a false-positive diagnosis could lead to unnecessary intervention, particularly if invasive diagnostic or therapeutic interventions are performed.</p><p class="headingAnchor" id="H3"><span class="h1">THE 18 TO 22 WEEK SCREENING EXAMINATION</span><span class="headingEndMark"> — </span>The optimum gestational age for screening for structural fetal cardiac anomalies is 18 to 22 weeks of gestation [<a href="#rid18">18</a>]. Fetal cardiac anatomy can be visualized well at this stage of pregnancy, a complete fetal anatomic survey can be performed, and there is time for further evaluation (eg, echocardiogram, genetic studies), if indicated, while the gestational age is still below the limit of postnatal viability.</p><p>It should be noted that some fetal cardiac conditions may not be detected until, or may first present after, 18 to 22 weeks of gestation. For example, fetal arrhythmias, myocarditis/cardiomyopathy, heart failure, valvular insufficiency or obstruction, and cardiac tumors have variable onset. In addition, small ventricular or atrial septal defects, minor valve lesions, partial anomalous pulmonary venous connection, and coronary artery anomalies are often not detected prenatally.</p><p class="headingAnchor" id="H2669655637"><span class="h2">Screening at other gestational ages</span><span class="headingEndMark"> — </span>The structure of the fetal heart can be reasonably assessed as early as 10 weeks of gestation, but visualization of cardiac structures in the first trimester is much better after 12+3 weeks. Consensus guidelines for first-trimester anatomy evaluation, including cardiac screening, in patients at high risk are available [<a href="#rid19">19</a>]. In a meta-analysis of first-trimester sonographic detection of major fetal heart anomalies (63 studies, &gt;300,000 fetuses), screening performance in the non-high-risk (low risk, unselected or mixed risk) population was sensitivity 55.8 percent and specificity 99.98 percent; in the high-risk population, these values were 67.74 and 99.75 percent, respectively [<a href="#rid20">20</a>]. First-trimester screening detected 64 percent of all antenatally detected major heart anomalies in non-high-risk patients and 80 percent of all antenatally detected major heart anomalies in high-risk patients. The detection rate was highest in studies using at least one outflow-tract view or color-flow Doppler imaging. (See <a class="local">'Standard cardiac evaluation'</a> below.)</p><p>Although the heart is larger after 30 weeks of gestation, optimum cardiac views may be difficult to obtain due to less space in the amniotic cavity for free fetal movement to a favorable position and shadowing from increasingly dense fetal ribs and spine.</p><p class="headingAnchor" id="H184751909"><span class="h1">STANDARD CARDIAC EVALUATION</span></p><p class="headingAnchor" id="H3277190525"><span class="h2">Four chambers and ventricular outflow tracts</span><span class="headingEndMark"> — </span>A standard fetal cardiac screening ultrasound examination includes assessment of the four chambers and ventricular outflow tracts (four chamber view, left and right ventricular outflow-tract views [LVOT and RVOT], RVOT/three-vessel view, and three-vessel-and-trachea view). The inclusion of views of the outflow tracts increases the likelihood of identifying conotruncal anomalies such as tetralogy of Fallot, transposition of the great arteries, double outlet right ventricle, and truncus arteriosus, as well as abnormalities of the semilunar valves. This examination is consistent with practice guidelines for sonographic screening of the fetal heart available from the International Society for Ultrasound in Obstetrics and Gynecology [<a href="#rid21">21</a>] and from a collaboration of the American Institute of Ultrasound in Medicine, American College of Radiology, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, and Society of Radiologists in Ultrasound [<a href="#rid22">22</a>]. </p><p>Formal evaluation of rhythm and cardiac function and detailed examination of cardiopulmonary anatomy are not part of a standard fetal cardiac evaluation, but rhythm abnormalities may be noted during routine screening and/or follow-up.</p><p>A meta-analysis evaluating the performance of different fetal sonographic protocols for diagnosis of fetal structural heart disease found that inclusion of the outflow tract in the standard examination increased detection rates of structural cardiac disease substantially: sensitivity 65 to 90 percent (four chambers with outlet tract or outlet tract and three vessels with trachea views) versus 52 percent with the four-chamber view alone [<a href="#rid23">23</a>]. However, there were wide variations in detection rates among screening studies, with some studies reporting only 15 percent detection of CHD. Factors affecting sensitivity include type of ultrasound practice (eg, university versus community hospital), operator training and experience, gestational age, maternal weight, fetal position, and type of abnormality [<a href="#rid24">24-26</a>]. Fetal echocardiography is a more sensitive, but less cost-effective, screening approach for pregnancies at low risk of CHD [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H184757147"><span class="h2">Procedure</span><span class="headingEndMark"> — </span>Fetal cardiac imaging should always be performed with the highest possible transducer frequency to maximize image resolution, and at the highest possible frame rate (preferably &gt;50 Hz), due to the rapid movement of the heart, which normally beats at 110 to 160 beats per minute. The standard four-chamber view can be obtained in 95 to 98 percent of second-trimester pregnancies [<a href="#rid28">28,29</a>]. It is obtained either from the long axis or apical view  (<a class="graphic graphic_diagnosticimage graphicRef61751" href="/d/graphic/61751.html" rel="external">image 1</a>). Usually it is easiest to start with a standard abdominal circumference plane of the fetal abdomen and angle the transducer cephalad on the fetus. The heart should occupy approximately one-third of the chest area. The four chambers of the fetal heart are seen with the left atrium most posterior (closest cardiac chamber to the spine) and the right ventricle most anterior (closest cardiac chamber to the sternum). The right and left atria and ventricles should be approximately symmetric in size. </p><p>Sweeps through the outflow tracts  (<a class="graphic graphic_diagnosticimage graphicRef95753" href="/d/graphic/95753.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef95754" href="/d/graphic/95754.html" rel="external">image 3</a>) should be obtained.</p><p>The mean axis of the fetal heart is approximately 45 degrees to the left of the midline (normal range 30 to 60 degrees). An increase in the axis can be a marker for outflow tract abnormalities [<a href="#rid30">30,31</a>] or a chest mass. The evaluation of cardiac axis has also been applied to screening in the first trimester [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8"><span class="h1">ADVANCED FETAL CARDIAC EVALUATION</span></p><p class="headingAnchor" id="H184758220"><span class="h2">Indications for echocardiography</span><span class="headingEndMark"> — </span>Fetal echocardiography provides more detailed evaluation of fetal cardiovascular structure and function than a basic ultrasound examination. It is performed in fetuses at a higher risk of CHD than would be expected for the general population and in fetuses who have or are suspected of having an abnormality on routine cardiac ultrasound screening. We believe that sonologists and sonographers performing the standard fetal cardiac assessment should have a low threshold for referral to fetal echocardiography to maintain a high detection rate for cardiac anomalies. The American Heart Association, American Society of Echocardiography, and Pediatric and Congenital Electrophysiology Society define increased risk of CHD as &gt;1 percent since the baseline risk of CHD in the general population is ≤1 percent [<a href="#rid18">18</a>].</p><p>Indications with a high-risk profile (estimated &gt;2 percent absolute risk) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal pregestational (preexisting) diabetes mellitus or diabetes mellitus diagnosed in the first trimester. (See  <a class="medical medical_review" href="/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal phenylketonuria (uncontrolled). (See  <a class="medical medical_review" href="/d/html/2919.html" rel="external">"Overview of phenylketonuria", section on 'Phenylalanine embryopathy (maternal PKU)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal autoantibodies (SSA/SSB), especially if a previous child had SSA/SSB-related heart disease. (See  <a class="medical medical_review" href="/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal use of potential cardiac teratogens (eg, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, angiotensin-converting enzyme inhibitors, retinoic acid, nonsteroidal anti-inflammatory drugs [NSAIDs] in the third trimester).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal first-trimester rubella infection. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of fetal myocarditis because of poor contractility or effusions on standard four-chamber cardiac examination. Fetal myocarditis may be related to maternal viral infections, such as coxsackie virus, adenovirus, parvovirus B19, and cytomegalovirus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy conceived by assisted reproduction technology (ART). (See  <a class="medical medical_review" href="/d/html/133130.html" rel="external">"Assisted reproductive technology: Infant and child outcomes", section on 'Congenital anomalies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CHD in first-degree relative of fetus (maternal, paternal, or sibling). (See  <a class="medical medical_review" href="/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Fetal evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First- or second-degree relative of the fetus with a disorder with Mendelian inheritance-associated CHD (eg, Noonan syndrome, tuberous sclerosis, Holt-Oram syndrome, velocardiofacial [DiGeorge] syndrome/22q11.2 deletion, Alagille syndrome, Williams syndrome). (See  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal cardiac abnormality (structural, functional, arrhythmia) suspected on a standard obstetric ultrasound examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal major noncardiac abnormality suspected on a standard obstetric ultrasound examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal genetic testing reveals a pathogenic variant, deletion, rearrangement, or aneuploidy  (<a class="graphic graphic_table graphicRef52621" href="/d/graphic/52621.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal tachycardia or bradycardia, or frequent or persistent irregular heart rhythm. (See  <a class="medical medical_review" href="/d/html/6765.html" rel="external">"Fetal arrhythmias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal nuchal translucency &gt;95<sup>th</sup> percentile (or ≥3 mm) on first-trimester sonogram  (<a class="graphic graphic_table graphicRef74699" href="/d/graphic/74699.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/435.html" rel="external">"Enlarged nuchal translucency and cystic hygroma", section on 'Congenital heart disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monochorionic twins. (See  <a class="medical medical_review" href="/d/html/130561.html" rel="external">"Twin pregnancy: Routine prenatal care", section on 'Screening for congenital anomalies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal hydrops or pericardial effusions. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Cardiovascular abnormalities'</a>.)</p><p></p><p>Indications with a less high-risk profile (estimated &gt;1 and &lt;2 percent absolute risk) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal medications (antiseizure, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> above recommended daily intake, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, NSAIDs in first/second trimester).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CHD in a second-degree relative of the fetus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal intraabdominal venous anomaly (eg, agenesis of the ductus venosus).</p><p></p><p>Fetal echocardiography is <strong>not </strong>indicated when the risk of cardiac abnormality is no higher than the baseline population risk (≤1 percent), such as a more distant relative with CHD or a close relative with acquired heart disease (eg, mitral valve prolapse), maternal gestational diabetes diagnosed in the third trimester, maternal obesity, abnormal maternal serum analytes or soft markers for aneuploidy, isolated single umbilical artery.</p><p class="headingAnchor" id="H12"><span class="h2">Procedures for advanced fetal cardiac assessment</span><span class="headingEndMark"> — </span>A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2Fpdf%2F10.1161%2F01.cir.0000437597.44550.5d&amp;token=kG6zG5al%2F6S5wdlrhe3R9xr%2BjeqQnaoUjAyVHj5pNZ5hqP9qvyibdRulWzsj3igkiFyLXUkhqlcobmXdEppu3nghENkhbM%2F%2BDVqt8HRrXuE%3D&amp;TOPIC_ID=6755" target="_blank">scientific statement</a> from the American Heart Association stated that a fetal echocardiogram should include standard views of the four chambers, the left and right ventricular outflow tracts, three vessels and trachea  (<a class="graphic graphic_diagnosticimage graphicRef95752" href="/d/graphic/95752.html" rel="external">image 4</a>), aortic and ductal arch, superior and inferior venae cavae, and short- and long-axis, as well as color and pulsed Doppler studies and M-mode to evaluate major veins, valves, rate, rhythm, etc [<a href="#rid18">18</a>]. Guidelines for the performance of fetal echocardiograms are also available from the International Society for Ultrasound in Obstetrics and Gynecology [<a href="#rid21">21</a>] and from the American Institute of Ultrasound in Medicine [<a href="#rid33">33</a>].</p><p>Ultrasound systems used for fetal echocardiography should be capable of performing two-dimensional, M-mode, and Doppler imaging [<a href="#rid34">34</a>]. Color and spectral Doppler are used to identify small vessels such as the pulmonary veins, ductus venosus, and ductus arteriosus, to assess valvular competence and flow patterns, and to examine the ventricular septum for defects. M-mode of atrial and ventricular wall motion are useful for analyzing rate and rhythm disturbances.</p><p>More advanced imaging techniques, which are beyond the scope of this review, include three-dimensional and four-dimensional echocardiography, tissue Doppler, strain and strain rate imaging, fetal electrocardiography, fetal magnetocardiography, and cardiovascular magnetic resonance imaging [<a href="#rid18">18,35</a>].</p><p class="headingAnchor" id="H184758185"><span class="h2">Diagnosis of specific cardiac abnormalities</span><span class="headingEndMark"> — </span>The sonographic appearance of specific anomalies is beyond the scope of this topic, but can be found in UpToDate topics on specific anomalies.</p><p class="headingAnchor" id="H184752453"><span class="h1">POSTDIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>When a fetal cardiac abnormality is diagnosed, additional evaluation and follow-up are indicated, as described below. Patients who have a normal standard fetal cardiac evaluation and echocardiography (if performed) generally do not require further evaluation unless there is an increased risk of development of fetal heart disease later in pregnancy.</p><p class="headingAnchor" id="H184757127"><span class="h2">Assessment for extracardiac anomalies</span><span class="headingEndMark"> — </span>The identification of a fetal cardiac abnormality should prompt a thorough search for extracardiac abnormalities, since these are detected in at least 20 to 40 percent of cases, depending on the population (eg, midtrimester fetuses versus live borns versus stillborns) [<a href="#rid36">36-38</a>]. Furthermore, cardiac anomalies are part of numerous fetal syndromes [<a href="#rid39">39,40</a>]. An analysis of data compiled from 20 registries of congenital malformations reported that approximately 4 percent of patients with cardiac anomalies had an identifiable syndrome [<a href="#rid40">40</a>]. Contemporary data incorporating advanced genetic testing (eg, exome sequencing) suggest that 25 to 30 percent of congenital heart disease has an identifiable origin, and this number is likely to increase as more sophisticated genetic testing becomes more widely available [<a href="#rid41">41</a>].</p><p>Although postnatal neurodevelopment may be affected by CHD, fetal brain magnetic resonance imaging (MRI) is not indicated unless a central nervous system abnormality has been identified on ultrasound and MRI findings will affect pregnancy management. Neuroimaging findings are generally not predictive of postnatal neurodevelopmental outcome. A meta-analysis of studies of prenatal ultrasound and MRI found that brain abnormalities, delay in head growth, and brain-sparing were observed in subgroups of fetuses with CHD [<a href="#rid42">42</a>]. However, the prognostic significance of these findings was unclear because large MRI studies were scarce, ultrasound data were biased toward severe and left-sided heart abnormalities, and long-term follow-up studies correlating prenatal and postnatal findings were limited [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1562441169"><span class="h2">Referral to specialists</span><span class="headingEndMark"> — </span>Given the complexity of fetal CHD, we recommend referral to a multidisciplinary team, including maternal-fetal medicine specialists, pediatric cardiologists, cardiothoracic surgeons, geneticists, and neonatologists. The purpose is to inform the patient about the suspected diagnosis and prognosis and discuss management options before and after delivery, including the preferred site for giving birth.</p><p class="headingAnchor" id="H184757325"><span class="h2">Genetic assessment</span><span class="headingEndMark"> — </span>Fetal genetic assessment is indicated because genetic abnormalities are common in fetuses with cardiac abnormalities, even when isolated  (<a class="graphic graphic_table graphicRef81423" href="/d/graphic/81423.html" rel="external">table 3</a>) [<a href="#rid26">26,38,44-47</a>]. In one series of 1510 fetuses with prenatally diagnosed CHD, 624 (41 percent) had an abnormal karyotype (aneuploidy in 562 cases, structural chromosomal abnormalities in 62 cases) [<a href="#rid48">48</a>]. The frequency of genetic abnormalities is higher prenatally than postnatally (41 percent [<a href="#rid48">48</a>] versus 13 percent [<a href="#rid49">49</a>]) because in utero death occurs in many cases, such as in the lethal autosomal trisomies (eg, trisomy 9 or 16).</p><p>The frequency of fetal aneuploidy varies depending on the structural anomaly. For example [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular septal defect (46 to 73 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Truncus arteriosus (19 to 78 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Double-outlet right ventricle/conotruncal malformations (6 to 43 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Coarctation/arch interruption (5 to 37 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid valve dysplasia (including Ebstein malformation, 4 to 16 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Tetralogy of Fallot (7 to 39 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoplastic left heart syndrome (HLHS; 4 to 9 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonic stenosis/atresia with intact ventricular septum (1 to 12 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Heterotaxy/cardiosplenic syndromes (0 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Transposition of great arteries (0 percent)</p><p></p><p>In addition, the 22q11 deletion has been associated with several cardiac anomalies, including interrupted aortic arch, truncus arteriosus, ventricular septal defect, and tetralogy of Fallot [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis"</a>.)</p><p>The two main approaches for genetic testing are (1) G-banding of fetal cells obtained via amniocentesis, with fluorescent in situ hybridization (FISH) to assess for microdeletions, such as 22q11, not detectable by visual banding techniques, and (2) chromosomal microarray, which detects submicroscopic chromosomal abnormalities in 5 percent of fetuses with ultrasound-detected anomalies and a normal G-band karyotype. Many fetuses with CHD will have microarray abnormalities, especially if noncardiac anomalies are also present [<a href="#rid41">41,50</a>]. Disadvantages of chromosomal microarray are that balanced rearrangements are not detectable and variants of unknown significance may be identified. Either approach is reasonable; the best choice is controversial and depends on factors such as physician/patient preference, cost, suspicion of trisomy or balanced rearrangement versus a microscopic gene defect, and time to obtain definitive results. (See  <a class="medical medical_review" href="/d/html/16683.html" rel="external">"Prenatal diagnosis of chromosomal imbalance: Chromosomal microarray"</a>.)</p><p>If these genetic tests are normal and there is a family history of a similar cardiac abnormality, long QT syndrome, or Noonan syndrome, then DNA mutation analysis and direct sequence analysis are options. Even without a suggestive history, exome and whole genome sequencing may show other genetic causes. These tests are expensive and time-consuming [<a href="#rid51">51,52</a>]. (See  <a class="medical medical_review" href="/d/html/1053.html" rel="external">"Congenital long QT syndrome: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature", section on 'Noonan syndrome'</a>.)</p><p class="headingAnchor" id="H184757331"><span class="h2">Ultrasound follow-up</span><span class="headingEndMark"> — </span>The necessity, timing, and frequency of serial assessment should be guided by the nature and severity of the lesion, presence of heart failure, anticipated timing and mechanism of progression, and the options available for prenatal and postpartum intervention [<a href="#rid18">18</a>]. </p><p>At least one follow-up examination early in the third trimester is reasonable to look for abnormalities that progressed in severity or may not have been detectable earlier in gestation, and have peripartum clinical implications. Some causes of progressive fetal cardiac dysfunction include worsening valvular insufficiency or obstruction, increasing obstruction to blood flow in the great arteries, or development/worsening of myocarditis or cardiomyopathy, arrhythmias, or cardiac tumors [<a href="#rid18">18</a>]. </p><p>The early to mid-third trimester is also an appropriate time to screen for growth restriction, which may be more prevalent in these fetuses or specific subtypes of CHD [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H184757472"><span class="h2">Evaluation of fetal well-being</span><span class="headingEndMark"> — </span>Fetuses with cardiac structural anomalies, functional disorders, or arrhythmias that have the potential to compromise tissue oxygen delivery are generally followed with antepartum testing, with intervention if results are abnormal. In one retrospective cohort study, fetuses with a genetic syndrome, extracardiac anomaly, or severe valvular regurgitation were at increased risk for fetal demise: 15 out of 197 fetuses (7.6 percent) with one or more of these risk factors died in utero versus 3 out of 270 fetuses (1 percent) without any of these risk factors [<a href="#rid57">57</a>]. Six of the 22 fetal deaths occurred at 20 to 23 weeks and 16 occurred at 26 to 41 weeks (including three deaths at 37, 39, and 41 weeks).</p><p>However, there is no strong evidence of the value of this practice and antepartum fetal testing with the nonstress test, biophysical profile, or fetal movement count has not been evaluated specifically in this clinical setting. The type of test depends on the underlying abnormality; for example, the biophysical profile is particularly useful in fetuses with arrhythmias and provides an opportunity to monitor development or progression of hydrops in any fetus with severely altered hemodynamics. (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p class="headingAnchor" id="H184759133"><span class="h2">Fetal therapy</span><span class="headingEndMark"> — </span>Transplacental medical therapy can improve the prognosis of some fetal arrhythmias. (See  <a class="medical medical_review" href="/d/html/6765.html" rel="external">"Fetal arrhythmias"</a>.)</p><p>Invasive in utero intervention (eg, aortic or pulmonary balloon valvuloplasty [<a href="#rid14">14</a>], atrial needle septoplasty [<a href="#rid15">15</a>]) may improve the prognosis of some lesions, such as HLHS or severe valvular abnormalities (eg, severe mitral regurgitation, aortic stenosis, pulmonary atresia); however, these interventions are performed at only a few fetal surgery centers and are considered investigational [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H184758853"><span class="h1">DELIVERY PLANNING</span><span class="headingEndMark"> — </span>Delivery should be planned at a facility with the appropriate level of care for the mother and neonate. Neonates with ductal-dependent lesions and most with critical cardiac lesions  (<a class="graphic graphic_table graphicRef103087" href="/d/graphic/103087.html" rel="external">table 4</a>) should be delivered at a facility with a level III neonatal intensive care unit (NICU) and pediatric cardiology expertise. If this is not feasible, transport arrangements should be established in advance of the delivery.</p><p class="headingAnchor" id="H184758282"><span class="h2">Timing and route</span><span class="headingEndMark"> — </span>Cesarean birth is performed for standard obstetric indications, as there is no evidence that route of delivery of fetuses with CHD affects outcome [<a href="#rid58">58</a>]. Based on observational data, induction of labor or scheduled cesarean before 39 weeks of gestation is not recommended in the absence of standard maternal or fetal concerns about well-being, as even early term delivery has been associated with worse outcomes after neonatal cardiac surgery [<a href="#rid18">18,59-61</a>]. One exception may be single ventricle defects, where earlier delivery may be beneficial [<a href="#rid62">62-64</a>]. (See  <a class="medical medical_review" href="/d/html/14370.html" rel="external">"Hypoplastic left heart syndrome: Anatomy, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H184758873"><span class="h2">Delivery room care</span><span class="headingEndMark"> — </span>Risk assessment for anticipated compromise in the delivery room or during the first few days of life is specific to the abnormality. Initial management of newborns with CHD at risk of postnatal hemodynamic instability or respiratory compromise during the fetal-neonatal transition is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Initial management'</a>.)</p><p>A committee from the American Heart Association made the following recommendations [<a href="#rid18">18</a>]:</p><p>Specialized delivery room care is recommended for fetuses with:</p><p class="bulletIndent1"><span class="glyph">●</span>d-transposition of the great arteries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained or uncontrolled tachyarrhythmias with heart failure or hydrops fetalis.</p><p></p><p>Specialized delivery room care planning is reasonable for fetuses with:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoplastic left heart syndrome with restrictive or intact atrial septum and abnormal pulmonary vein flow (pulmonary vein forward/reversed flow ratio &lt;3) or abnormal hyperoxia test in the third trimester.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete heart block and low ventricular rate, cardiac dysfunction, or hydrops fetalis.</p><p></p><p>Specialized delivery room care planning may be considered in fetuses with:</p><p class="bulletIndent1"><span class="glyph">●</span>Tetralogy of Fallot with absent pulmonary valve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ebstein anomaly with hydrops fetalis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total anomalous pulmonary venous return, obstructed.</p><p></p><p>Specialized delivery room care is not needed for fetuses with:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild tetralogy of Fallot, ventricular septal defect, atrioventricular septal defect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shunt lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most ductal-dependent lesions, but initiation of prostaglandin E1 may be indicated in the NICU.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Controlled arrhythmias.</p><p></p><p class="headingAnchor" id="H4000363922"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115414.html" rel="external">"Society guideline links: Congenital heart disease in infants and children"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for screening</strong> – We suggest prenatal screening for fetal cardiac abnormalities (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Prenatal diagnosis provides parents an opportunity to obtain prognostic information prior to birth, learn about treatment options before and after delivery, reach decisions concerning the management approach that is best for their family, and plan for specific needs at birth. Depending on the lesion, prenatal diagnosis may reduce perinatal morbidity and mortality. (See <a class="local">'Benefits and risks of prenatal screening and diagnosis of CHD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – The optimum gestational age for screening for structural fetal cardiac anomalies is 18 to 22 weeks of gestation. However, some fetal cardiac conditions may not be detected until, or may first present, later in gestation. Fetal arrhythmias, myocarditis/cardiomyopathy, heart failure, valvular insufficiency or obstruction, and cardiac tumors have variable timing of onset. Small ventricular or atrial septal defects, minor valve lesions, partial anomalous pulmonary venous connection, and coronary artery anomalies are often not detected prenatally. (See <a class="local">'The 18 to 22 week screening examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basic fetal cardiac assessment</strong> – A basic fetal cardiac assessment should include a four-chamber view and the outflow tracts and be a part of every second-trimester fetal evaluation, regardless of risk factors. Sonologists and sonographers performing these assessments should have a low threshold for referral to fetal echocardiography to maintain a high detection rate for cardiac anomalies. (See <a class="local">'Standard cardiac evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal echocardiography</strong> – Fetal echocardiography should be performed in fetuses at a higher risk of congenital heart disease (CHD) than would be expected for the general population (see <a class="local">'Advanced fetal cardiac evaluation'</a> above). We agree with the American Institute of Ultrasound in Medicine, International Society for Ultrasound in Obstetrics and Gynecology, American Heart Association (AHA), American Society of Echocardiography, and Pediatric and Congenital Electrophysiology Society guidance describing fetal, maternal, and familial factors conferring an increased risk of fetal cardiac disease. (See <a class="local">'Indications for echocardiography'</a> above.)</p><p></p><p class="bulletIndent1">A fetal echocardiogram should include standard views of the four chambers, the left and right ventricular outflow tracts, three vessels and trachea  (<a class="graphic graphic_diagnosticimage graphicRef95752" href="/d/graphic/95752.html" rel="external">image 4</a>), aortic and ductal arch, superior and inferior venae cavae, and short- and long-axis, as well as color and pulsed Doppler studies and M-mode to evaluate major veins, valves, rate, rhythm, etc. (See <a class="local">'Procedures for advanced fetal cardiac assessment'</a> above.)</p><p></p><p class="bulletIndent1">In fetuses undergoing echocardiography, a detailed fetal anatomic survey should also be performed. Extracardiac abnormalities are detected in at least 20 to 40 percent of fetuses with a cardiac abnormality. Approximately 4 percent of patients with cardiac anomalies have an identifiable syndrome. (See <a class="local">'Assessment for extracardiac anomalies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – There is an increased risk of genetic abnormalities, particularly aneuploidy or 22q11 deletion, in fetuses with CHD; the frequency depends on the specific lesion. Current approaches for testing include (1) G-banding of fetal cells obtained via amniocentesis, with fluorescent in situ hybridization (FISH) to assess for microdeletions, such as 22q11, not detectable by visual banding techniques, and (2) chromosomal microarray, which detects submicroscopic chromosomal abnormalities in 5 percent of fetuses with ultrasound-detected anomalies and a normal G-band karyotype. Either approach is reasonable. When karyotype and microarray are normal, especially in the presence of extracardiac malformations, exome or whole genome sequencing may provide further information. (See <a class="local">'Genetic assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of sonographic follow-up</strong> – The necessity, timing, and frequency of follow-up ultrasound assessment should be guided by the nature and severity of the lesion, presence of heart failure, anticipated timing and mechanism of progression, and the options available for prenatal and postpartum intervention. We suggest at least one follow-up examination early in the third trimester to look for abnormalities that progressed in severity or may not have been detectable earlier in gestation. For most lesions other than small muscular ventricular septal defects, we typically perform serial examinations at least monthly to assess for disease progression and further patient counseling. (See <a class="local">'Ultrasound follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery</strong> – Delivery should be planned at a facility with the appropriate level of care for the mother and neonate. Early delivery and cesarean delivery are generally performed only for standard obstetric indications. (See <a class="local">'Timing and route'</a> above.)</p><p></p><p class="bulletIndent1">Risk assessment for anticipated compromise in the delivery room or during the first few days of life is specific to the disease. We agree with AHA guidance for delivery room preparation and neonatal care. (See <a class="local">'Delivery room care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Data and Statistics on Congenital Heart Defects https://www.cdc.gov/ncbddd/heartdefects/data.html (Accessed on February 15, 2023).</li><li class="breakAll">Deaths: Leading Causes for 2019. National Vital Statistics Reports. Volume 70, Number 9. 2021. Available at: https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf (Accessed on February 16, 2023).</li><li><a class="nounderline abstract_t">Holland BJ, Myers JA, Woods CR Jr. Prenatal diagnosis of critical congenital heart disease reduces risk of death from cardiovascular compromise prior to planned neonatal cardiac surgery: a meta-analysis. Ultrasound Obstet Gynecol 2015; 45:631.</a></li><li><a class="nounderline abstract_t">Li YF, Zhou KY, Fang J, et al. Efficacy of prenatal diagnosis of major congenital heart disease on perinatal management and perioperative mortality: a meta-analysis. World J Pediatr 2016; 12:298.</a></li><li><a class="nounderline abstract_t">Thakur V, Dutil N, Schwartz SM, Jaeggi E. Impact of prenatal diagnosis on the management and early outcome of critical duct-dependent cardiac lesions. Cardiol Young 2018; 28:548.</a></li><li><a class="nounderline abstract_t">Khoshnood B, Lelong N, Houyel L, et al. Impact of prenatal diagnosis on survival of newborns with four congenital heart defects: a prospective, population-based cohort study in France (the EPICARD Study). BMJ Open 2017; 7:e018285.</a></li><li><a class="nounderline abstract_t">Verheijen PM, Lisowski LA, Stoutenbeek P, et al. Prenatal diagnosis of congenital heart disease affects preoperative acidosis in the newborn patient. J Thorac Cardiovasc Surg 2001; 121:798.</a></li><li><a class="nounderline abstract_t">Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. Circulation 1999; 99:916.</a></li><li><a class="nounderline abstract_t">Kumar RK, Newburger JW, Gauvreau K, et al. Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally. Am J Cardiol 1999; 83:1649.</a></li><li><a class="nounderline abstract_t">Punn R, Silverman NH. Fetal predictors of urgent balloon atrial septostomy in neonates with complete transposition. J Am Soc Echocardiogr 2011; 24:425.</a></li><li><a class="nounderline abstract_t">Du Marchie Sarvaas GJ, Trivedi KR, Hornberger LK, et al. Radiofrequency-assisted atrial septoplasty for an intact atrial septum in complex congenital heart disease. Catheter Cardiovasc Interv 2002; 56:412.</a></li><li><a class="nounderline abstract_t">Lowenthal A, Kipps AK, Brook MM, et al. Prenatal diagnosis of atrial restriction in hypoplastic left heart syndrome is associated with decreased 2-year survival. Prenat Diagn 2012; 32:485.</a></li><li><a class="nounderline abstract_t">Glatz AC, Gaynor JW, Rhodes LA, et al. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth. J Thorac Cardiovasc Surg 2008; 136:767.</a></li><li><a class="nounderline abstract_t">Freud LR, McElhinney DB, Marshall AC, et al. Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients. Circulation 2014; 130:638.</a></li><li><a class="nounderline abstract_t">Marshall AC, van der Velde ME, Tworetzky W, et al. Creation of an atrial septal defect in utero for fetuses with hypoplastic left heart syndrome and intact or highly restrictive atrial septum. Circulation 2004; 110:253.</a></li><li><a class="nounderline abstract_t">Araujo Júnior E, Tonni G, Chung M, et al. Perinatal outcomes and intrauterine complications following fetal intervention for congenital heart disease: systematic review and meta-analysis of observational studies. Ultrasound Obstet Gynecol 2016; 48:426.</a></li><li><a class="nounderline abstract_t">Friedman KG, Sleeper LA, Freud LR, et al. Improved technical success, postnatal outcome and refined predictors of outcome for fetal aortic valvuloplasty. Ultrasound Obstet Gynecol 2018; 52:212.</a></li><li><a class="nounderline abstract_t">Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183.</a></li><li><a class="nounderline abstract_t">AIUM Practice Parameter for the Performance of Detailed Diagnostic Obstetric Ultrasound Examinations Between 12 Weeks 0 Days and 13 Weeks 6 Days. J Ultrasound Med 2021; 40:E1.</a></li><li><a class="nounderline abstract_t">Karim JN, Bradburn E, Roberts N, et al. First-trimester ultrasound detection of fetal heart anomalies: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2022; 59:11.</a></li><li><a class="nounderline abstract_t">Carvalho JS, Axt-Fliedner R, Chaoui R, et al. ISUOG Practice Guidelines (updated): fetal cardiac screening. Ultrasound Obstet Gynecol 2023; 61:788.</a></li><li><a class="nounderline abstract_t">AIUM-ACR-ACOG-SMFM-SRU Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations. J Ultrasound Med 2018; 37:E13. (available online at https://onlinelibrary.wiley.com/doi/10.1002/jum.14831)</a></li><li><a class="nounderline abstract_t">Li Y, Hua Y, Fang J, et al. Performance of different scan protocols of fetal echocardiography in the diagnosis of fetal congenital heart disease: a systematic review and meta-analysis. PLoS One 2013; 8:e65484.</a></li><li><a class="nounderline abstract_t">Tegnander E, Eik-Nes SH. The examiner's ultrasound experience has a significant impact on the detection rate of congenital heart defects at the second-trimester fetal examination. Ultrasound Obstet Gynecol 2006; 28:8.</a></li><li><a class="nounderline abstract_t">Wong SF, Chan FY, Cincotta RB, et al. Factors influencing the prenatal detection of structural congenital heart diseases. Ultrasound Obstet Gynecol 2003; 21:19.</a></li><li><a class="nounderline abstract_t">Friedberg MK, Silverman NH, Moon-Grady AJ, et al. Prenatal detection of congenital heart disease. J Pediatr 2009; 155:26.</a></li><li><a class="nounderline abstract_t">Pinto NM, Nelson R, Puchalski M, et al. Cost-effectiveness of prenatal screening strategies for congenital heart disease. Ultrasound Obstet Gynecol 2014; 44:50.</a></li><li><a class="nounderline abstract_t">Carvalho JS, Mavrides E, Shinebourne EA, et al. Improving the effectiveness of routine prenatal screening for major congenital heart defects. Heart 2002; 88:387.</a></li><li><a class="nounderline abstract_t">Tegnander E, Eik-Nes SH, Linker DT. Incorporating the four-chamber view of the fetal heart into the second-trimester routine fetal examination. Ultrasound Obstet Gynecol 1994; 4:24.</a></li><li><a class="nounderline abstract_t">Shipp TD, Bromley B, Hornberger LK, et al. Levorotation of the fetal cardiac axis: a clue for the presence of congenital heart disease. Obstet Gynecol 1995; 85:97.</a></li><li><a class="nounderline abstract_t">Smith RS, Comstock CH, Kirk JS, Lee W. Ultrasonographic left cardiac axis deviation: a marker for fetal anomalies. Obstet Gynecol 1995; 85:187.</a></li><li><a class="nounderline abstract_t">Sinkovskaya ES, Chaoui R, Karl K, et al. Fetal cardiac axis and congenital heart defects in early gestation. Obstet Gynecol 2015; 125:453.</a></li><li><a class="nounderline abstract_t">AIUM Practice Parameter for the Performance of Fetal Echocardiography. J Ultrasound Med 2020; 39:E5.</a></li><li><a class="nounderline abstract_t">Abuhamad A. Color and pulsed Doppler in fetal echocardiography. Ultrasound Obstet Gynecol 2004; 24:1.</a></li><li><a class="nounderline abstract_t">Lloyd DFA, Pushparajah K, Simpson JM, et al. Three-dimensional visualisation of the fetal heart using prenatal MRI with motion-corrected slice-volume registration: a prospective, single-centre cohort study. Lancet 2019; 393:1619.</a></li><li><a class="nounderline abstract_t">Greenwood RD, Rosenthal A, Parisi L, et al. Extracardiac abnormalities in infants with congenital heart disease. Pediatrics 1975; 55:485.</a></li><li><a class="nounderline abstract_t">Wallgren EI, Landtman B, Rapola J. Extracardiac malformations associated with congenital heart disease. Eur J Cardiol 1978; 7:15.</a></li><li><a class="nounderline abstract_t">Song MS, Hu A, Dyamenahalli U, et al. Extracardiac lesions and chromosomal abnormalities associated with major fetal heart defects: comparison of intrauterine, postnatal and postmortem diagnoses. Ultrasound Obstet Gynecol 2009; 33:552.</a></li><li><a class="nounderline abstract_t">Copel JA, Pilu G, Kleinman CS. Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography. Am J Obstet Gynecol 1986; 154:1121.</a></li><li><a class="nounderline abstract_t">Pajkrt E, Weisz B, Firth HV, Chitty LS. Fetal cardiac anomalies and genetic syndromes. Prenat Diagn 2004; 24:1104.</a></li><li><a class="nounderline abstract_t">Russell MW, Chung WK, Kaltman JR, Miller TA. Advances in the Understanding of the Genetic Determinants of Congenital Heart Disease and Their Impact on Clinical Outcomes. J Am Heart Assoc 2018; 7.</a></li><li><a class="nounderline abstract_t">Jansen FA, Everwijn SM, Scheepjens R, et al. Fetal brain imaging in isolated congenital heart defects - a systematic review and meta-analysis. Prenat Diagn 2016; 36:601.</a></li><li><a class="nounderline abstract_t">Paladini D, Alfirevic Z, Carvalho JS, et al. ISUOG consensus statement on current understanding of the association of neurodevelopmental delay and congenital heart disease: impact on prenatal counseling. Ultrasound Obstet Gynecol 2017; 49:287.</a></li><li><a class="nounderline abstract_t">Copel JA, Cullen M, Green JJ, et al. The frequency of aneuploidy in prenatally diagnosed congenital heart disease: an indication for fetal karyotyping. Am J Obstet Gynecol 1988; 158:409.</a></li><li><a class="nounderline abstract_t">Wimalasundera RC, Gardiner HM. Congenital heart disease and aneuploidy. Prenat Diagn 2004; 24:1116.</a></li><li><a class="nounderline abstract_t">Tuuli MG, Dicke JM, Stamilio DM, et al. Prevalence and likelihood ratios for aneuploidy in fetuses diagnosed prenatally with isolated congenital cardiac defects. Am J Obstet Gynecol 2009; 201:390.e1.</a></li><li><a class="nounderline abstract_t">Mone F, Walsh C, Mulcahy C, et al. Prenatal detection of structural cardiac defects and presence of associated anomalies: a retrospective observational study of 1262 fetal echocardiograms. Prenat Diagn 2015; 35:577.</a></li><li><a class="nounderline abstract_t">Moore JW, Binder GA, Berry R. Prenatal diagnosis of aneuploidy and deletion 22q11.2 in fetuses with ultrasound detection of cardiac defects. Am J Obstet Gynecol 2004; 191:2068.</a></li><li><a class="nounderline abstract_t">Ferencz C, Neill CA, Boughman JA, et al. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J Pediatr 1989; 114:79.</a></li><li><a class="nounderline abstract_t">Jansen FA, Blumenfeld YJ, Fisher A, et al. Array comparative genomic hybridization and fetal congenital heart defects: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 45:27.</a></li><li><a class="nounderline abstract_t">Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science 2015; 350:1262.</a></li><li><a class="nounderline abstract_t">Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 2013; 498:220.</a></li><li><a class="nounderline abstract_t">Wallenstein MB, Harper LM, Odibo AO, et al. Fetal congenital heart disease and intrauterine growth restriction: a retrospective cohort study. J Matern Fetal Neonatal Med 2012; 25:662.</a></li><li><a class="nounderline abstract_t">Perez-Delboy A, Simpson LL. Prenatal sonographic diagnosis of congenital heart disease and intrauterine growth restriction: a case-control study. J Clin Ultrasound 2007; 35:376.</a></li><li><a class="nounderline abstract_t">Itsukaichi M, Kikuchi A, Yoshihara K, et al. Changes in fetal circulation associated with congenital heart disease and their effects on fetal growth. Fetal Diagn Ther 2011; 30:219.</a></li><li><a class="nounderline abstract_t">Matthiesen NB, Henriksen TB, Agergaard P, et al. Congenital Heart Defects and Indices of Placental and Fetal Growth in a Nationwide Study of 924 422 Liveborn Infants. Circulation 2016; 134:1546.</a></li><li><a class="nounderline abstract_t">Divanovic A, Bowers K, Michelfelder E, et al. Intrauterine fetal demise after prenatal diagnosis of congenital heart disease: assessment of risk. Prenat Diagn 2016; 36:142.</a></li><li><a class="nounderline abstract_t">Peterson AL, Quartermain MD, Ades A, et al. Impact of mode of delivery on markers of perinatal hemodynamics in infants with hypoplastic left heart syndrome. J Pediatr 2011; 159:64.</a></li><li><a class="nounderline abstract_t">Costello JM, Polito A, Brown DW, et al. Birth before 39 weeks' gestation is associated with worse outcomes in neonates with heart disease. Pediatrics 2010; 126:277.</a></li><li><a class="nounderline abstract_t">Cnota JF, Gupta R, Michelfelder EC, Ittenbach RF. Congenital heart disease infant death rates decrease as gestational age advances from 34 to 40 weeks. J Pediatr 2011; 159:761.</a></li><li><a class="nounderline abstract_t">Costello JM, Pasquali SK, Jacobs JP, et al. Gestational age at birth and outcomes after neonatal cardiac surgery: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database. Circulation 2014; 129:2511.</a></li><li><a class="nounderline abstract_t">Kipps AK, Feuille C, Azakie A, et al. Prenatal diagnosis of hypoplastic left heart syndrome in current era. Am J Cardiol 2011; 108:421.</a></li><li><a class="nounderline abstract_t">Levey A, Glickstein JS, Kleinman CS, et al. The impact of prenatal diagnosis of complex congenital heart disease on neonatal outcomes. Pediatr Cardiol 2010; 31:587.</a></li><li><a class="nounderline abstract_t">Atz AM, Travison TG, Williams IA, et al. Prenatal diagnosis and risk factors for preoperative death in neonates with single right ventricle and systemic outflow obstruction: screening data from the Pediatric Heart Network Single Ventricle Reconstruction Trial(∗). J Thorac Cardiovasc Surg 2010; 140:1245.</a></li></ol></div><div id="topicVersionRevision">Topic 6755 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/ncbddd/heartdefects/data.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Data and Statistics on Congenital Heart Defects https://www.cdc.gov/ncbddd/heartdefects/data.html (Accessed on February 15, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Deaths: Leading Causes for 2019. National Vital Statistics Reports. Volume 70, Number 9. 2021. Available at: https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf (Accessed on February 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904437" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prenatal diagnosis of critical congenital heart disease reduces risk of death from cardiovascular compromise prior to planned neonatal cardiac surgery: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059744" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy of prenatal diagnosis of major congenital heart disease on perinatal management and perioperative mortality: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409551" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of prenatal diagnosis on the management and early outcome of critical duct-dependent cardiac lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122798" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of prenatal diagnosis on survival of newborns with four congenital heart defects: a prospective, population-based cohort study in France (the EPICARD Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279423" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prenatal diagnosis of congenital heart disease affects preoperative acidosis in the newborn patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027815" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392870" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324642" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fetal predictors of urgent balloon atrial septostomy in neonates with complete transposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112899" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Radiofrequency-assisted atrial septoplasty for an intact atrial septum in complex congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511219" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prenatal diagnosis of atrial restriction in hypoplastic left heart syndrome is associated with decreased 2-year survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18805283" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25052401" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226215" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Creation of an atrial septal defect in utero for fetuses with hypoplastic left heart syndrome and intact or highly restrictive atrial septum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799734" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Perinatal outcomes and intrauterine complications following fetal intervention for congenital heart disease: systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543953" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improved technical success, postnatal outcome and refined predictors of outcome for fetal aortic valvuloplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763516" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852128" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : AIUM Practice Parameter for the Performance of Detailed Diagnostic Obstetric Ultrasound Examinations Between 12 Weeks 0 Days and 13 Weeks 6 Days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34369613" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : First-trimester ultrasound detection of fetal heart anomalies: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37267096" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ISUOG Practice Guidelines (updated): fetal cardiac screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30308091" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : AIUM-ACR-ACOG-SMFM-SRU Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23750263" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Performance of different scan protocols of fetal echocardiography in the diagnosis of fetal congenital heart disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16736449" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The examiner's ultrasound experience has a significant impact on the detection rate of congenital heart defects at the second-trimester fetal examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528156" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Factors influencing the prenatal detection of structural congenital heart diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394031" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prenatal detection of congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357432" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cost-effectiveness of prenatal screening strategies for congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231598" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Improving the effectiveness of routine prenatal screening for major congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12797222" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incorporating the four-chamber view of the fetal heart into the second-trimester routine fetal examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7800334" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Levorotation of the fetal cardiac axis: a clue for the presence of congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824228" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ultrasonographic left cardiac axis deviation: a marker for fetal anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568997" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fetal cardiac axis and congenital heart defects in early gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31846540" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : AIUM Practice Parameter for the Performance of Fetal Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229909" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Color and pulsed Doppler in fetal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30910324" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Three-dimensional visualisation of the fetal heart using prenatal MRI with motion-corrected slice-volume registration: a prospective, single-centre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/124046" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Extracardiac abnormalities in infants with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/648575" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Extracardiac malformations associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350566" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Extracardiac lesions and chromosomal abnormalities associated with major fetal heart defects: comparison of intrauterine, postnatal and postmortem diagnoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2939723" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614851" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fetal cardiac anomalies and genetic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523523" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Advances in the Understanding of the Genetic Determinants of Congenital Heart Disease and Their Impact on Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27187181" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Fetal brain imaging in isolated congenital heart defects - a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27891680" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : ISUOG consensus statement on current understanding of the association of neurodevelopmental delay and congenital heart disease: impact on prenatal counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341415" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The frequency of aneuploidy in prenatally diagnosed congenital heart disease: an indication for fetal karyotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614848" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Congenital heart disease and aneuploidy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716116" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence and likelihood ratios for aneuploidy in fetuses diagnosed prenatally with isolated congenital cardiac defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25663276" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prenatal detection of structural cardiac defects and presence of associated anomalies: a retrospective observational study of 1262 fetal echocardiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592293" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prenatal diagnosis of aneuploidy and deletion 22q11.2 in fetuses with ultrasound detection of cardiac defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521249" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25319878" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Array comparative genomic hybridization and fetal congenital heart defects: a systematic review and meta-analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785492" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23665959" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : De novo mutations in histone-modifying genes in congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21823904" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fetal congenital heart disease and intrauterine growth restriction: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583562" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prenatal sonographic diagnosis of congenital heart disease and intrauterine growth restriction: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849766" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Changes in fetal circulation associated with congenital heart disease and their effects on fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742737" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Congenital Heart Defects and Indices of Placental and Fetal Growth in a Nationwide Study of 924 422 Liveborn Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26618782" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intrauterine fetal demise after prenatal diagnosis of congenital heart disease: assessment of risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21414630" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of mode of delivery on markers of perinatal hemodynamics in infants with hypoplastic left heart syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20603261" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Birth before 39 weeks' gestation is associated with worse outcomes in neonates with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676411" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Congenital heart disease infant death rates decrease as gestational age advances from 34 to 40 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795388" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Gestational age at birth and outcomes after neonatal cardiac surgery: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21624547" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prenatal diagnosis of hypoplastic left heart syndrome in current era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20165844" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The impact of prenatal diagnosis of complex congenital heart disease on neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561642" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prenatal diagnosis and risk factors for preoperative death in neonates with single right ventricle and systemic outflow obstruction: screening data from the Pediatric Heart Network Single Ventricle Reconstruction Trial(∗).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
